Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies-Reference-Cited by-同舟云学术

Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies

Published:2008-10 Issue:5 Volume:17 Page:499-505
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Fabi Alessandra,Metro Giulio,Ferretti Gianluigi,Giannarelli Diana,Di Cosimo Serena,Papaldo Paola,Mottolese Marcella,Carlini Paolo,Felici Alessandra,Russillo Michelangelo,Cognetti Francesco

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference29 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer;Seshadri;J Clin Oncol,1993

3. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy;Ross;Stem Cells,1998

4. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease;Cobleigh;J Clin Oncol,1999

5. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer;Vogel;J Clin Oncol,2002

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Is There a Role for Multiple Lines of Anti-HER2 Therapies Administered Beyond Progression in HER2-Mutated Non-Small Cell Lung Cancer? A Case Report and Literature Review;Oncology and Therapy;2020-07-07

2. Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience;Tumori Journal;2019-12-18

3. Real-World Evidence: A Comparison of the Australian Herceptin Program and Clinical Trials of Trastuzumab for HER2-Positive Metastatic Breast Cancer;PharmacoEconomics;2016-05-20

4. Potential of overcoming resistance to HER2-targeted therapies through the PI3K/Akt/mTOR pathway;The Breast;2015-10

5. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study;PLOS ONE;2015-09-16